Definitive treatment patterns and survival in stage II non-small cell lung cancer

被引:3
|
作者
Yan, Sherry X. [1 ]
Qureshi, Muhammad M. [2 ,3 ]
Suzuki, Kei [3 ,4 ]
Dyer, Michael [2 ,3 ]
Truong, Minh Tam [2 ,3 ]
Litle, Virginia [3 ,4 ]
Mak, Kimberley S. [2 ,3 ]
机构
[1] Boston Med Ctr, One Boston Med Ctr Pl, Boston, MA 02118 USA
[2] Boston Med Ctr, Dept Radiat Oncol, 830 Harrison Ave, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, 72 E Concord St, Boston, MA 02118 USA
[4] Boston Med Ctr, Dept Surg, Div Thorac Surg, 830 Harrison Ave,3rd Floor, Boston, MA 02118 USA
关键词
Non-small cell lung cancer; Treatment patterns; Survival; Surgery; Radiotherapy; BODY RADIATION-THERAPY; PHASE-III; TNM CLASSIFICATION; UNITED-STATES; FRACTIONATED RADIOTHERAPY; TRIAL; CONCURRENT; MANAGEMENT; PROPOSALS; GROUPINGS;
D O I
10.1016/j.lungcan.2018.07.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: This study delineated definitive treatment patterns for Stage II non-small cell lung cancer (NSCLC) in the United States and evaluated survival by treatment approach. Materials and Methods: Patients with clinically-staged Stage II NSCLC treated with surgery-based therapy, chemoradiation, conventionally-fractionated radiation (CFR), or stereotactic body radiotherapy (SBRT) were identified using the National Cancer Database (NCDB). Median survival was estimated using Kaplan-Meier analysis. Crude and adjusted hazard ratios (HR) and 95% confidence intervals were computed using Cox regression modeling. Results: Between 2004-2012, 19,749 patients met study criteria: 13,382 (67.8%) underwent surgery-based treatment, 4,310 (21.8%) received chemoradiation, 1,606 (8.1%) received CFR, and 451 (2.3%) received SBRT. Surgery and SBRT utilization increased over time while CFR and chemoradiation decreased (all p < 0.002). Patients receiving radiation-based treatments were older, with more comorbidities, and higher T/N stage (all p < 0.0001). With median follow-up of 25.2 months, median survival was 51.6, 23.3, 15.4, and 23.7 months for surgery-based treatment, chemoradiation, CFR, and SBRT, respectively (p < 0.0001). On multivariate analysis, chemoradiation (HR 1.67 [1.59-1.75], p < 0.0001), CFR (HR 2.38 [2.22-2.55], p < 0.0001), and SBRT (HR 1.76 [1.53-2.01], p < 0.0001) were associated with decreased survival versus surgery-based treatment. CFR was associated with decreased survival versus chemoradiation (HR 1.52 [1.41-1.63], p < 0.0001) and SBRT (HR 1.39 [1.19-1.61], p < 0.0001). SBRT was associated with similar survival versus chemoradiation (HR 1.10 [0.95-1.27], p = 0.212). Conclusion: NCDB data demonstrate increasing use of surgery-based treatments and SBRT for Stage II NSCLC over time. Radiation-based therapies were associated with decreased survival compared to surgery. CFR was associated with decreased survival compared to chemoradiation and SBRT.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 50 条
  • [1] Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer
    Kapadia, Nirav S.
    Valle, Luca F.
    George, Julie A.
    Jagsi, Reshma
    D'Amico, Thomas A.
    Dexter, Elisabeth U.
    Vigneau, Fawn D.
    Kong, Feng Ming
    ANNALS OF THORACIC SURGERY, 2017, 104 (06): : 1881 - 1888
  • [2] Treatment of stage II non-small cell lung cancer
    Scott, WJ
    Howington, J
    Movsas, B
    CHEST, 2003, 123 (01) : 188S - 201S
  • [3] Patterns of treatment and survival among older patients with stage III non-small cell lung cancer
    Driessen, Elisabeth J. M.
    Schulkes, Karlijn J. G.
    Dingemans, Anne-Marie C.
    van Loon, Judith G. M.
    Hamaker, Marije E.
    Aarts, Mieke J.
    Janssen-Heijnen, Maryska L. G.
    LUNG CANCER, 2018, 116 : 55 - 61
  • [4] Patterns of Care and Survival Outcomes in Stage II Non-Small Cell Lung Cancer: An Analysis of the National Cancer Database
    Yan, S. X.
    Qureshi, M. M.
    Truong, M. T.
    Mak, K. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 251 - 251
  • [5] Surgical treatment of stage I and II non-small cell lung cancer
    Klotz, Laura V.
    Winter, Hauke
    ONKOLOGE, 2018, 24 (12): : 1009 - 1014
  • [6] Regional disparities in treatment and survival of early stage non-small cell lung cancer
    Crowell, Richard E.
    Goetz, Therese
    Wiggins, Charles
    Magana, Eric
    ETHNICITY & DISEASE, 2007, 17 (02) : 358 - 364
  • [7] Inoperable early stage non-small cell lung cancer: Comorbidity, patterns of care and survival
    Smith, S. L.
    Palma, D.
    Parhar, T.
    Alexander, C. S.
    Wai, E. S.
    LUNG CANCER, 2011, 72 (01) : 39 - 44
  • [8] Carboplatin and gemcitabine in the palliative treatment of stage IV non-small cell lung cancer: Definitive results of a phase II trial
    Tassinari, D
    Fochessati, F
    Arcangeli, V
    Sartori, S
    Agostini, V
    Fantini, M
    Genestreti, G
    Grassia, S
    Ioli, G
    Imola, M
    Iorio, D
    Mianulli, AM
    Monticelli, G
    Oliverio, G
    Panzini, I
    Papi, M
    Poggi, B
    Polselli, A
    Pulini, S
    Tamburini, E
    Fattori, PP
    Ravaioli, A
    TUMORI JOURNAL, 2004, 90 (01): : 54 - 59
  • [9] Hypofractionated Radiotherapy as Definitive Treatment of Stage I Non-Small Cell Lung Cancer in Older Patients
    Ahmad, Ehatsham
    Sandhu, Ajay P.
    Fuster, Mark M.
    Messer, Karen
    Pu, Minya
    Nobiensky, Polly
    Bazhenova, Lyudmila
    Seagren, Stephen
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (03): : 254 - 258
  • [10] Hypofractionated radiotherapy as definitive treatment of stage I non-small cell lung cancer in older patients
    Ahmad, E.
    Sandhu, A. P.
    Fuster, M.
    Messer, K.
    Pu, M.
    Nobiensky, P.
    Bazhenova, L.
    Seagren, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S478 - S478